Trial Profile
A Phase II Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Temsirolimus (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- 01 Jun 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 01 Jun 2010 Actual end date (February 2010) added as reported by ClinicalTrials.gov.
- 01 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.